Articles from FairJourney Biologics S.A.

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney’s ongoing strategic growth plan, and will significantly bolster the Company’s antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its global presence with a key biotechnology hub in the US.

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced it has established a Scientific Advisory Board (SAB) to support its strategy for ongoing growth and innovation. The advisory board comprises renowned industry experts appointed to support the identification of strategic opportunities, enhance scientific excellence, and drive the development of cutting-edge technologies. This alignment ensures the Company remains at the forefront of antibody discovery, addressing market needs and future trends.

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced the appointment of Dr Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering. A leader in the field, Marc’s appointment will ensure the Company is prepared to meet the evolving needs of its customers within the therapeutic antibody space, bolstering the Company’s capabilities across its cutting-edge platforms and fostering new strategic partnerships with global biotech and pharma companies.

FairJourney Biologics S.A., leader in the discovery and optimization of antibodies, today announced, after the overwhelming success of the 2021 ANTIBODY SERIES conference, planning for a larger scale 2022 ANTIBODY SERIES are underway.

FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, today announced the launch of the “THE ANTIBODY SERIES” - a 1-day conference bringing together top experts in the antibody field to explore the latest innovation within antibody drug discovery. The conference is being launched in Porto, Portugal, celebrating FairJourney Biologics’ inauguration of their new purpose built, state-of-the-art facilities. Online registration to the event has been made available free for a limited period here: https://fjb.pt/the-antibody-series-2021/